Role of p21 signaling pathway in response to MC & DMC DNA Interstrand Crosslinks

p21信号通路在MC反应中的作用

基本信息

  • 批准号:
    8667188
  • 负责人:
  • 金额:
    $ 11.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The mitomycins are a family of antitumor antibiotics made by Streptomyces. One member of this family, mitomycin C (MC), is currently used to treat certain cancers. Its mode of action has been extensively examined. In comparison, 10-decarbamoyl mitomycin C (DMC) has not been the object of such intense investigation. It has recently been found to form similar or identical adducts with DNA as mitomycin C (MC). In particular, DMC generates a unique stereoisomeric interstrand crosslink (beta isomer, ¿-ICL). Although the DNA-adducts of both drugs share common structural features, the biochemical responses to the two drugs are different. In particular, contrary to MC, the DNA-adducts generated by DMC treatment (¿-ICL) rapidly activate a p53-independent signal transduction pathway. Thus, the study MC-DMC provides an ideal model for identifying structural features determining the cell signaling outcome in the presence or the absence of a functioning p53 pathway. The central hypothesis of this proposal is that the differences in the local DNA structures of the mitosene-alpha and mitosene-beta crosslink adducts ( ¿-ICL and ¿-ICL) are responsible for the different biochemical responses produced by the two compounds in particular, we hypothesize that DMC provokes a PI3K/Akt/p21 cell death pathway due to the specific DNA-adducts formed. In order to correlate MC and DMC-adducts structures with the role of p21 in the toxicity of the ¿- ICL and ¿-ICL, the following three aims will be achieved: 1) Synthesis of the alpha and beta DNA crosslinks of MC and DMC via biomimetic and post-oligomerization methods. 2) Determination of the sequence selectivity (CG or GC) for the ¿-ICL of decarbamoyl mitomycin C (DMC) through analysis of the favored cross-linking pathway. This will reveal the orientation of the drug in the DNA duplex: upstream or downstream. 3) Finally, the role of p21 in the upstream p53-independent signaling pathway in response to MC/DMC and these crosslinks will be determined by using flow cytometer to verify the cell cycle arrest stage, Western blot analysis to reveal the p21 phosphorylation status and immunocytochemistry to localize p21. The involvement of the PI3K/Akt signaling pathway in p21 activation will be examined. PCR array will be performed to identify genes regulated by the ¿- and ¿-ICLs.
说明(申请人提供):丝裂霉素是由链霉菌生产的一类抗肿瘤抗生素。该家族的成员之一,丝裂霉素C(MC),目前被用于治疗某些癌症。它的行动模式已经得到了广泛的审查。相比之下,10-脱氨基甲酰丝裂霉素C(DMC)并不是如此密集的研究对象。最近发现它与DNA形成类似或相同的加合物,如丝裂霉素C(MC)。特别是,DMC产生一种独特的立体异构体链间交联物(β异构体,?-ICL)。虽然两种药物的DNA加合物具有共同的结构特征,但对两种药物的生化反应不同。特别是,与MC相反,DMC处理产生的DNA加合物(?-ICL)迅速激活了一条不依赖于p53的信号转导途径。因此,MC-DMC的研究提供了一个理想的模型,用于识别在存在或不存在功能正常的P53通路的情况下,决定细胞信号转导结果的结构特征。这一建议的中心假设是,丝裂素-α和丝裂素-β交联物(?-ICL和?-ICL)局部DNA结构的差异是导致这两种化合物产生不同生化反应的原因。特别是,我们假设DMC通过形成特定的DNA加合物而引发PI3K/Akt/p21细胞死亡途径。为了将MC和DMC加合物结构与p21在β-ICL和β-ICL毒性中的作用联系起来,将实现以下三个目标:1)通过仿生和后齐聚方法合成MC和DMC的α和βDNA交联链。2)通过分析有利的交联途径,测定脱氨甲酰丝裂霉素C(DMC)的序列选择性(CG或GC)。这将揭示药物在DNA双链中的定位:上游或下游。3)最后,通过流式细胞仪检测细胞周期停滞阶段,Western印迹分析p21蛋白的磷酸化状态,免疫细胞化学方法检测p21蛋白的定位,确定p21在MC/DMC及其交联物应答的p53非依赖性信号通路中的作用。我们将研究PI3K/Akt信号通路在p21激活中的作用。将进行聚合酶链式反应阵列,以确定受-和-ICL调控的基因。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elise Champeil其他文献

Elise Champeil的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elise Champeil', 18)}}的其他基金

Identification of critical cellular pathways triggered by mitomycins interstrand crosslinks
丝裂霉素链间交联触发的关键细胞途径的鉴定
  • 批准号:
    10629504
  • 财政年份:
    2023
  • 资助金额:
    $ 11.81万
  • 项目类别:
Determination of P21 upstream signaling in the toxicity of MC and DMC DNA interstrand crosslinks (Student: Melissa Rosas)
确定 MC 和 DMC DNA 链间交联毒性中的 P21 上游信号传导(学生:Melissa Rosas)
  • 批准号:
    10377882
  • 财政年份:
    2021
  • 资助金额:
    $ 11.81万
  • 项目类别:
Differences in RNA expression in response to MC and DMC stereoisomeric interstrandcrosslinks (Student: Christina Gonzalez)
MC 和 DMC 立体异构链间交联反应中 RNA 表达的差异(学生:Christina Gonzalez)
  • 批准号:
    10378888
  • 财政年份:
    2021
  • 资助金额:
    $ 11.81万
  • 项目类别:
Determination of P21 downstream signaling in the toxicity of MC and DMC DNA interstrand crosslinks (Student: Kameza Harun)
确定 MC 和 DMC DNA 链间交联毒性中的 P21 下游信号传导(学生:Kameza Harun)
  • 批准号:
    10378838
  • 财政年份:
    2021
  • 资助金额:
    $ 11.81万
  • 项目类别:
Role of p21 in the toxicity of MC and DMC DNA Interstrand Crosslinks
p21 在 MC 和 DMC DNA 链间交联毒性中的作用
  • 批准号:
    10377556
  • 财政年份:
    2014
  • 资助金额:
    $ 11.81万
  • 项目类别:
Role of p21 in the toxicity of MC and DMC DNA Interstrand Crosslinks
p21 在 MC 和 DMC DNA 链间交联毒性中的作用
  • 批准号:
    9912784
  • 财政年份:
    2014
  • 资助金额:
    $ 11.81万
  • 项目类别:
Role of p21 signaling pathway in response to MC & DMC DNA Interstrand Crosslinks
p21信号通路在MC反应中的作用
  • 批准号:
    9091621
  • 财政年份:
    2014
  • 资助金额:
    $ 11.81万
  • 项目类别:
Role of p21 in the toxicity of MC and DMC DNA Interstrand Crosslinks
p21 在 MC 和 DMC DNA 链间交联毒性中的作用
  • 批准号:
    10596866
  • 财政年份:
    2014
  • 资助金额:
    $ 11.81万
  • 项目类别:
Role of p21 in the toxicity of MC and DMC DNA Interstrand Crosslinks
p21 在 MC 和 DMC DNA 链间交联毒性中的作用
  • 批准号:
    10596876
  • 财政年份:
    2014
  • 资助金额:
    $ 11.81万
  • 项目类别:
Differences in RNA and miRNA expression in response to MC and DMC stereoisomeric interstrand crosslinks (Student: Christina Gonzalez)
MC 和 DMC 立体异构体链间交联反应中 RNA 和 miRNA 表达的差异(学生:Christina Gonzalez)
  • 批准号:
    10544084
  • 财政年份:
    2014
  • 资助金额:
    $ 11.81万
  • 项目类别:

相似海外基金

Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
  • 批准号:
    10374792
  • 财政年份:
    2021
  • 资助金额:
    $ 11.81万
  • 项目类别:
Elucidation and prevention of the mechanism of hepatic sinusoidal obstruction syndrome (SOS) induced by DNA alkylating agents
DNA烷化剂诱发肝窦阻塞综合征(SOS)机制的阐明和预防
  • 批准号:
    21K15255
  • 财政年份:
    2021
  • 资助金额:
    $ 11.81万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
  • 批准号:
    10570900
  • 财政年份:
    2021
  • 资助金额:
    $ 11.81万
  • 项目类别:
Development of individualized therapy by elucidation of molecular mechanisms for hypermutation phenotype induced by treatment with alkylating agents in glioma
通过阐明神经胶质瘤中烷化剂治疗诱导的超突变表型的分子机制来开发个体化治疗
  • 批准号:
    18K09004
  • 财政年份:
    2018
  • 资助金额:
    $ 11.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Reversing intrinsic cancer cell resistance to alkylating agents by histone deacetylase inhibition
通过组蛋白脱乙酰酶抑制逆转癌细胞对烷化剂的内在耐药性
  • 批准号:
    214657440
  • 财政年份:
    2012
  • 资助金额:
    $ 11.81万
  • 项目类别:
    Research Grants
Rerouting alkylating agents to the mitochondria for cancer therapy
将烷化剂重新路由至线粒体用于癌症治疗
  • 批准号:
    247842
  • 财政年份:
    2011
  • 资助金额:
    $ 11.81万
  • 项目类别:
    Studentship Programs
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8105413
  • 财政年份:
    2010
  • 资助金额:
    $ 11.81万
  • 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8271313
  • 财政年份:
    2010
  • 资助金额:
    $ 11.81万
  • 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8730259
  • 财政年份:
    2010
  • 资助金额:
    $ 11.81万
  • 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8676463
  • 财政年份:
    2010
  • 资助金额:
    $ 11.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了